MCID: INS001
MIFTS: 65

Insulinoma

Categories: Rare diseases, Gastrointestinal diseases, Endocrine diseases, Cancer diseases

Aliases & Classifications for Insulinoma

MalaCards integrated aliases for Insulinoma:

Name: Insulinoma 38 12 76 53 59 29 55 6 44 15 73
Islet Cell Adenoma 12 73
Experimental Organism Islet Cell Adenoma Neoplasm 73
Insulin-Producing Tumor of Islet Cells 12
Adenoma Islet Cell 55
Islet Cell Tumor 73

Characteristics:

Orphanet epidemiological data:

59
insulinoma
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Ireland),1-9/1000000 (Worldwide),1-9/1000000 (Japan); Age of onset: All ages;

Classifications:



Summaries for Insulinoma

NIH Rare Diseases : 53 Insulinoma is a type of pancreatic neuroendocrine tumor (pancreatic NET), which refers to a group of rare tumors that form in the hormone-making cells of the pancreas. Insulinomas, specifically, produce too much insulin, a hormone that reduces the level of sugar in the blood by helping it move into cells. As a result, people with insulinomas generally have very low blood sugar levels which can be associated with anxiety, confusion, hunger, a fast heart rate, and sweating. In severe cases, it can lead to seizures, coma or even death. Ninty percent of insulinomas are benign (noncancerous). In most cases, the underlying cause of insulinoma is unknown. However, people with specific genetic syndromes such as multiple endocrine neoplasia type I, Von Hippel-Lindau syndrome, Neurofibromatosis type 1, and tuberous sclerosis are at risk of insulinomas and other endocrine tumors. Treatment generally includes surgery to remove the tumor.

MalaCards based summary : Insulinoma, also known as islet cell adenoma, is related to glucagonoma and hyperproinsulinemia. An important gene associated with Insulinoma is MEN1 (Menin 1), and among its related pathways/superpathways are Aldosterone synthesis and secretion and Glucose / Energy Metabolism. The drugs Everolimus and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include Pancreas, the pancreas and pancreas, and related phenotypes are hearing abnormality and abnormality of vision

Disease Ontology : 12 An adenoma that is located in the pancreas and is characterized by overproduction of insulin.

Wikipedia : 76 An insulinoma is a tumor of the pancreas that is derived from beta cells and secretes insulin. It is a... more...

Related Diseases for Insulinoma

Diseases related to Insulinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 155)
# Related Disease Score Top Affiliating Genes
1 glucagonoma 30.5 CHGA SCT SST
2 hyperproinsulinemia 30.4 INS SCT
3 duodenal ulcer 30.3 INS SCT SST
4 neuroendocrine tumor 30.1 CHGA INSM1 MEN1 SST
5 hypoglycemia 29.9 ABCC8 GCG GCK INS
6 islet cell tumor 29.9 CHGA INS MEN1 SST
7 multiple endocrine neoplasia, type i 29.9 CHGA INS MEN1 SCT SST
8 hyperinsulinemic hypoglycemia 29.8 ABCC8 GCK INS SST
9 carcinoid syndrome 29.8 CHGA MEN1 SST
10 glucose intolerance 29.6 GCG GCK INS
11 gastrinoma 29.6 CHGA INS MEN1 SCT SST
12 hyperinsulinism 29.6 ABCC8 GCK INS SST
13 zollinger-ellison syndrome 29.5 CHGA MEN1 SCT SST
14 dumping syndrome 29.2 GCG INS SCT SST
15 hyperinsulinemic hypoglycemia, familial, 2 28.3 ABCC8 CHGA INS SCT SST
16 hyperglycemia 26.0 ABCC8 GCG GCK GLP1R IAPP INS
17 diabetes mellitus, noninsulin-dependent 25.4 ABCC8 GCG GCK GLP1R IAPP INS
18 diabetes mellitus 23.9 ABCC8 GCG GCK GLP1R IAPP INS
19 insulinoma tumor suppressor gene locus 12.1
20 metastatic insulinoma 12.0
21 adult-onset non-insulinoma persistent hyperinsulinemic hypoglycemia 11.9
22 pancreatic neuroendocrine tumor 11.3
23 microinvasive cervical squamous cell carcinoma 10.9 INSM1 PTPRN
24 fallopian tube endometrioid adenocarcinoma 10.9 INSM1 PTPRN
25 maturity-onset diabetes of the young, type 2 10.8 GCK INS
26 duodenal somatostatinoma 10.7 INS SST
27 postgastrectomy syndrome 10.7 INS SST
28 postural hypotension 10.7 INS SST
29 pancreatic somatostatinoma 10.7 MEN1 SST
30 type 1 diabetes mellitus 7 10.7 INS PTPRN
31 fallopian tube adenocarcinoma 10.7 INSM1 PTPRN
32 hormone producing pituitary cancer 10.6 MEN1 SST
33 pancreatitis 10.6
34 type 1 diabetes mellitus 13 10.5 INS PTPRN
35 type 1 diabetes mellitus 15 10.5 GCG INS
36 pituitary gland disease 10.5 INS MEN1 SST
37 gastrointestinal neuroendocrine benign tumor 10.5 CHGA SST
38 adenoma of the pancreas 10.5 CHGA SST
39 gastric neuroendocrine neoplasm 10.5 CHGA SST
40 pancreatic agenesis 1 10.5 PDX1 SCT
41 acromegaly 10.5 INS MEN1 SST
42 pancreatic gastrinoma 10.5 MEN1 SCT SST
43 gastrointestinal neuroendocrine tumor 10.5 CHGA SST
44 gestational diabetes 10.4 GCK INS PTPRN
45 hyperpituitarism 10.4 INS SST
46 pituitary carcinoma 10.4 CHGA SST
47 somatostatinoma 10.3 CHGA INS SST
48 munchausen by proxy 10.3 ABCC8 GCK
49 multiple endocrine neoplasia 10.3
50 carcinoid tumors, intestinal 10.3 CHGA MEN1 SST

Graphical network of the top 20 diseases related to Insulinoma:



Diseases related to Insulinoma

Symptoms & Phenotypes for Insulinoma

Human phenotypes related to Insulinoma:

59 32 (show all 34)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hearing abnormality 59 32 occasional (7.5%) Occasional (29-5%) HP:0000364
2 abnormality of vision 59 32 occasional (7.5%) Occasional (29-5%) HP:0000504
3 anxiety 59 32 occasional (7.5%) Occasional (29-5%) HP:0000739
4 hyperinsulinemic hypoglycemia 59 32 hallmark (90%) Very frequent (99-80%) HP:0000825
5 hyperhidrosis 59 32 hallmark (90%) Very frequent (99-80%) HP:0000975
6 seizures 59 32 hallmark (90%) Very frequent (99-80%) HP:0001250
7 lethargy 59 32 occasional (7.5%) Occasional (29-5%) HP:0001254
8 coma 59 32 occasional (7.5%) Occasional (29-5%) HP:0001259
9 tremor 59 32 hallmark (90%) Very frequent (99-80%) HP:0001337
10 nonketotic hypoglycemia 59 32 hallmark (90%) Very frequent (99-80%) HP:0001958
11 palpitations 59 32 hallmark (90%) Very frequent (99-80%) HP:0001962
12 recurrent hypoglycemia 59 32 hallmark (90%) Very frequent (99-80%) HP:0001988
13 zollinger-ellison syndrome 59 32 frequent (33%) Frequent (79-30%) HP:0002044
14 abnormal rapid eye movement sleep 59 32 occasional (7.5%) Occasional (29-5%) HP:0002494
15 polyphagia 59 32 frequent (33%) Frequent (79-30%) HP:0002591
16 generalized muscle weakness 59 32 frequent (33%) Frequent (79-30%) HP:0003324
17 paresthesia 59 32 occasional (7.5%) Occasional (29-5%) HP:0003401
18 increased body weight 59 32 frequent (33%) Frequent (79-30%) HP:0004324
19 abnormality of the pancreatic islet cells 59 32 hallmark (90%) Very frequent (99-80%) HP:0006476
20 pituitary prolactin cell adenoma 59 32 frequent (33%) Frequent (79-30%) HP:0006767
21 fluctuations in consciousness 59 32 frequent (33%) Frequent (79-30%) HP:0007159
22 primary hyperparathyroidism 59 32 frequent (33%) Frequent (79-30%) HP:0008200
23 fasting hyperinsulinemia 59 32 hallmark (90%) Very frequent (99-80%) HP:0008283
24 transient global amnesia 59 32 hallmark (90%) Very frequent (99-80%) HP:0010534
25 abnormality of pain sensation 59 32 occasional (7.5%) Occasional (29-5%) HP:0010832
26 reactive hypoglycemia 59 32 frequent (33%) Frequent (79-30%) HP:0012051
27 fatigue 59 32 occasional (7.5%) Occasional (29-5%) HP:0012378
28 neoplasm of the adrenal gland 59 32 occasional (7.5%) Occasional (29-5%) HP:0100631
29 neuroendocrine neoplasm 59 32 occasional (7.5%) Occasional (29-5%) HP:0100634
30 insomnia 59 32 occasional (7.5%) Occasional (29-5%) HP:0100785
31 behavioral abnormality 59 Frequent (79-30%)
32 hyperinsulinemia 59 Very frequent (99-80%)
33 reduced consciousness/confusion 59 Frequent (79-30%)
34 abnormality of higher mental function 59 Occasional (29-5%)

MGI Mouse Phenotypes related to Insulinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.9 GLP1R INS INSM1 MEN1 PDX1 PTPRN
2 growth/size/body region MP:0005378 9.7 GCK WFS1 GLP1R IAPP INS INSM1
3 homeostasis/metabolism MP:0005376 9.5 GLP1R IAPP INS INSM1 KCNA5 MEN1

Drugs & Therapeutics for Insulinoma

Drugs for Insulinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 197)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177
2
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
3
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
4
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 341031-54-7, 557795-19-4 5329102
5
Somatostatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 38916-34-6, 51110-01-1 53481605
6
Pancrelipase Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 53608-75-6
7
Zinc Approved, Investigational Phase 4,Phase 2 7440-66-6 23994
8 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1
11 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1
13 Angiogenesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
14 Angiogenesis Modulating Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
15 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
16 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
17 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
18 Hypoglycemic Agents Phase 4,Phase 2,Phase 1,Early Phase 1,Not Applicable
19 pancreatin Phase 4,Phase 2,Phase 1,Not Applicable
20 insulin Phase 4,Phase 2,Not Applicable
21 Insulin, Globin Zinc Phase 4,Phase 2,Not Applicable
22 Fluorodeoxyglucose F18 Phase 4,Phase 2
23
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
24
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
25
Levoleucovorin Approved, Investigational Phase 2, Phase 3,Phase 1 68538-85-2
26
Oxaliplatin Approved, Investigational Phase 2, Phase 3,Phase 1 61825-94-3 5310940 9887054 43805 6857599
27
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
28 lanreotide Approved Phase 3,Phase 2 108736-35-2
29
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
30
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3,Phase 1 59-30-3 6037
31
leucovorin Approved, Nutraceutical Phase 2, Phase 3,Phase 3,Phase 1 58-05-9 143 6006
32 Pancreatic Polypeptide Investigational Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 59763-91-6
33 Antimetabolites Phase 2, Phase 3,Phase 1
34 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 1
35 Central Nervous System Depressants Phase 3,Phase 2,Not Applicable
36 Liver Extracts Phase 3,Phase 2,Phase 1,Not Applicable
37 Calcimimetic Agents Phase 3
38 Calcium, Dietary Phase 3,Phase 2,Phase 1
39 Cinacalcet Hydrochloride Phase 3
40 Adjuvants, Anesthesia Phase 3
41 Analgesics Phase 3
42 Analgesics, Opioid Phase 3
43 Anesthetics Phase 3,Not Applicable
44 Anesthetics, General Phase 3
45 Anesthetics, Intravenous Phase 3
46 Narcotics Phase 3
47 Peripheral Nervous System Agents Phase 3,Phase 2
48 Angiopeptin Phase 3,Phase 2
49 Pharmaceutical Solutions Phase 3,Phase 2,Not Applicable
50 Dihydroxyphenylalanine Phase 3

Interventional clinical trials:

(show top 50) (show all 166)
# Name Status NCT ID Phase Drugs
1 Clinical Effectiveness of Serum Chromogranin A Levels on Diagnostic of Pancreatic Neuroendocrine Tumors Unknown status NCT02759718 Phase 4
2 Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China Recruiting NCT02842749 Phase 4 everolimus
3 Nonfunctional Pancreatic NET and PET Imaging Recruiting NCT02621541 Phase 4
4 A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01525550 Phase 4 sunitinib
5 Pasireotide Treatment for Neuroendocrine Tumor Withdrawn NCT02779257 Phase 4 Pasireotide;Diazoxide
6 Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Unknown status NCT00227617 Phase 2, Phase 3 5-fluorouracil;leucovorin;oxaliplatin
7 Cinacalcet to Treat Familial Primary Hyperparathyroidism Completed NCT00325104 Phase 3
8 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
9 Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour Completed NCT00842348 Phase 3 lanreotide (Autogel formulation)
10 Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours Completed NCT00353496 Phase 3 lanreotide (Autogel formulation);Placebo
11 Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors Completed NCT00510068 Phase 3 Everolimus;Everolimus Placebo
12 A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET) Recruiting NCT02288377 Phase 2, Phase 3 lanreotide;Placebo
13 Phase III Study of Sulfatinib in Treating Advanced Pancreatic Neuroendocrine Tumors Recruiting NCT02589821 Phase 3 Sulfatinib
14 18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety Recruiting NCT03042416 Phase 3 18F-DOPA
15 Non-functioning Pancreatic Neuroendocrine Tumors in MEN1: Somatostatin Analogs Versus NO Treatment Not yet recruiting NCT02705651 Phase 3 Somatostatin-Analog
16 Cabozantinib S-malate in Treating Patients With Neuroendocrine Tumors Previously Treated With Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery Not yet recruiting NCT03375320 Phase 3 Cabozantinib S-malate
17 A Study Of Sunitinib Compared To Placebo For Patients With Advanced Pancreatic Islet Cell Tumors Terminated NCT00428597 Phase 3 sunitinib malate;Placebo
18 Activity and Safety of Everolimus+Octreotide LAR+Metformin in Advanced Pancreatic Well-differentiated NETs Unknown status NCT02294006 Phase 2 Everolimus plus Octreotide LAR plus Metformin
19 Docetaxel With or Without Low-dose, Short Course Sunitinib in Refractory Solid Tumors Unknown status NCT01803503 Phase 2 Docetaxel;Sunitinib
20 Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer Unknown status NCT02188550 Phase 2 everolimus and letrozole
21 Recombinant Anti-tumor and Anti-virus Protein for Injection to Treat Advanced Neuroendocrine Tumors Unknown status NCT02455596 Phase 2 Recombinant anti-tumor and anti-virus protein for injection (Novaferon)
22 Effect of Gelofusine on GLP1-receptor Imaging Completed NCT02541734 Phase 1, Phase 2 Gelofusine;Placebo
23 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
24 Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00131911 Phase 2 sorafenib tosylate
25 Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00075439 Phase 2 gefitinib
26 Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer Completed NCT00454363 Phase 2 Pazopanib Hydrochloride
27 PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00017199 Phase 2 bortezomib
28 Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery Completed NCT00416767 Phase 2 fluorouracil;irinotecan hydrochloride;leucovorin calcium
29 Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00027638 Phase 2 thalidomide
30 Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors Completed NCT00602082 Phase 2 capecitabine;cisplatin;streptozocin
31 AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors Completed NCT00427349 Phase 2 AMG 706;octreotide
32 Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer Completed NCT00096083 Phase 2 isolated perfusion;melphalan
33 BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy. Completed NCT01658436 Phase 2 BEZ235 (Stage 1)
34 Chemotherapy Plus Endostatin in Advanced Pancreatic Neuroendocrine Tumor Completed NCT01845675 Phase 2 temozolomide or dacarbazine-based chemotherapy, endostatin
35 AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors Completed NCT01024387 Phase 2 AMG 479
36 Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors Completed NCT01121562 Phase 2 Sunitinib
37 A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET) Completed NCT02806648 Phase 2 Palbociclib
38 Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery Completed NCT02101918 Phase 2
39 Combination Chemotherapy in Patients With Zollinger-Ellison Syndrome and Tumors of the Pancreas Completed NCT00001165 Phase 2 combined chemotherapy with streptozotocin, 5-fluorouracil, and doxorubicin
40 Interferon and Octreotide to Treat Zollinger-Ellison Syndrome and Advanced Non-B Islet Cell Cancer Completed NCT00001228 Phase 2 Interferon
41 68-Ga-labeled Octreotide Analogues PET in Duodenal-pancreatic Neuroendocrine Tumours Completed NCT01673906 Phase 2 Diagnostic work up
42 Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET Completed NCT02231762 Phase 2 Lanreotide Autogel 120 mg;Temozolomide (TMZ)
43 Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy Completed NCT00363051 Phase 2 Everolimus 10 mg;Octreotide Depot
44 68Ga-OPS202 Study for Diagnostic Imaging of GEP NET Completed NCT02162446 Phase 1, Phase 2 68Ga-OPS202
45 Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization Completed NCT00434109 Phase 2 Sunitinib malate
46 KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors Completed NCT02250885 Phase 2 Selinexor
47 A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers Completed NCT02132468 Phase 2 fosbretabulin tromethamine
48 Pazopanib as Single Agent in Advanced NETs Completed NCT01280201 Phase 2 Pazopanib
49 The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric Acid Completed NCT00001191 Phase 2 Pantoprazole;Omeprazole
50 Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET) Completed NCT00610129 Phase 2 MK-0646

Search NIH Clinical Center for Insulinoma

Cochrane evidence based reviews: insulinoma

Genetic Tests for Insulinoma

Genetic tests related to Insulinoma:

# Genetic test Affiliating Genes
1 Insulinoma 29

Anatomical Context for Insulinoma

The Foundational Model of Anatomy Ontology organs/tissues related to Insulinoma:

19
The Pancreas

MalaCards organs/tissues related to Insulinoma:

41
Pancreas, Liver, Heart, Pancreatic Islet, Testes, Lung, Lymph Node
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Insulinoma:
# Tissue Anatomical CompartmentCell Relevance
1 Pancreas Islets of Langerhans Mature Beta Cells Affected by disease

Publications for Insulinoma

Articles related to Insulinoma:

(show top 50) (show all 968)
# Title Authors Year
1
Minimally Invasive Versus Open Treatment for Benign Sporadic Insulinoma Comparison of Short-Term and Long-Term Outcomes. ( 29691623 )
2018
2
Incidence and management of postoperative hyperglycemia in patients undergoing insulinoma resection. ( 29923016 )
2018
3
Probing the Effect of Physiological Concentrations of IL-6 on Insulin Secretion by INS-1 832/3 Insulinoma Cells under Diabetic-Like Conditions. ( 29966345 )
2018
4
Glucose Management during Insulinoma Resection Using Real-Time Subcutaneous Continuous Glucose Monitoring. ( 29977620 )
2018
5
<i>Nfe2l1-</i> silenced insulinoma cells acquire aggressiveness and chemoresistance. ( 29203613 )
2018
6
Insulinoma presenting with post-prandial hypoglycaemia following fundoplication. ( 29367876 )
2018
7
Insulinoma-associated protein 1 is a sensitive and specific marker of neuroendocrine lung neoplasms in cytology specimens. ( 29360191 )
2018
8
Pro-inflammatory cytokines attenuate glucose-stimulated insulin secretion from INS-1E insulinoma cells by restricting mitochondrial pyruvate oxidation capacity - Novel mechanistic insight from real-time analysis of oxidative phosphorylation. ( 29953508 )
2018
9
Insulinoma-Associated Protein 1 Immunostain: A Diagnostic Tool for Pulmonary Small Cell Carcinoma in Cytology. ( 29936498 )
2018
10
Insulinoma-associated 1: A novel nuclear marker in Merkel cell carcinoma (cutaneous neuroendocrine carcinoma). ( 29148079 )
2018
11
Robotic enucleation for pediatric insulinoma with MEN1 syndrome: a case report and literature review. ( 29921249 )
2018
12
Rare malignant insulinoma with multiple liver metastases derived from ectopic pancreas: 3-year follow-up and literature review. ( 29662318 )
2018
13
Insulinoma-associated protein 1 is a novel sensitive and specific marker for small cell carcinoma of the prostate. ( 29885405 )
2018
14
Akt/p27<sup>kip1</sup> Pathway Is Not Involved in Human Insulinoma Tumorigenesis. ( 29853883 )
2018
15
The Effect of Everolimus on Refractory Hypoglycemia in a Patient with Inoperable Metastatic Insulinoma Evaluated by Continuous Glucose Monitoring. ( 29877259 )
2018
16
Screening key candidate genes and pathways involved in insulinoma by microarray analysis. ( 29851790 )
2018
17
Arterial calcium stimulation with hepatic venous sampling predicts the localization and size of the insulinoma as well as postoperative weight loss. ( 29966460 )
2018
18
Notch pathway inhibition targets chemoresistant insulinoma cancer stem cells. ( 29175872 )
2018
19
Utility of contrast-enhanced computed tomography in the evaluation of canine insulinoma location. ( 29806550 )
2018
20
17I^-estradiol protects INS-1 insulinoma cells from mitophagy via G protein-coupled estrogen receptors and the PI3K/Akt signaling pathway. ( 29436590 )
2018
21
Diagnostic challenges in a patient with an occult insulinoma:<sup>68A </sup>Ga-DOTA-exendin-4 PET/CT and <sup>68</sup>Ga-DOTATATE PET/CT. ( 29636947 )
2018
22
Clinical Value of<sup>18</sup>F-FDOPA PET/CT With Contrast Enhancement and Without Carbidopa Premedication in Patients with Insulinoma. ( 29277794 )
2018
23
Insulinoma Masquerading as Transient Neurocognitive Impairment. ( 29753794 )
2018
24
Contrast-enhanced harmonic endoscopic ultrasound: A better choice to guide EUS-FNI for insulinoma. ( 29776875 )
2018
25
An observational analysis of insulinoma from 1 single institution. ( 29319794 )
2018
26
68Ga DOTA-Exendin PET/CT for Detection of Insulinoma in a Patient With Persistent Hyperinsulinemic Hypoglycemia. ( 29877881 )
2018
27
Localisation of occult extra-pancreatic insulinoma using glucagon-like peptide-1 receptor molecular imaging. ( 29314520 )
2018
28
Hypoglycemia caused by insulinoma. A review of a case series treated at a tertiary hospital. ( 29657066 )
2018
29
Hyperinsulinemic hypoglycemia without insulinoma: Think of activating glucokinase mutation. ( 29555163 )
2018
30
Peptide receptor radionuclide therapy with <sup>177</sup>Lu-DOTA-TATE as a promising treatment of malignant insulinoma: a series of case reports and literature review. ( 29949120 )
2018
31
First experience of robotic spleen-preserving distal pancreatectomy in a child with insulinoma. ( 29121944 )
2017
32
Laparoscopic surgery for solitary insulinoma in the absence of IOUS. ( 28782747 )
2017
33
Insulinoma and Chronic Kidney Disease: An Uncommon Conundrum Not to Be Overlooked. ( 29200897 )
2017
34
Endoscopic ultrasound-guided ethanol ablation therapy for pancreatic insulinoma: an unusual strategy. ( 28458908 )
2017
35
Decreased levels of Fibroblast Growth Factor 21 are correlated with improved hypoglycemia in patients with insulinoma. ( 28225059 )
2017
36
Quantitative proteomic profiling of the extracellular matrix of pancreatic islets during the angiogenic switch and insulinoma progression. ( 28071719 )
2017
37
T372R Mutation Status in Yin Yang 1 Gene in Insulinoma Patients. ( 28472826 )
2017
38
Association of Insulinoma and Type 2 Diabetes Mellitus. ( 28835758 )
2017
39
Insulinoma-associated protein 1 (INSM1) differentiates carcinoid tumourlets of the lung from pulmonary meningothelial-like nodules. ( 29274092 )
2017
40
Pyruvate kinase M1 interacts with A-Raf and inhibits endoplasmic reticulum stress-induced apoptosis by activating MEK1/ERK pathway in mouse insulinoma cells. ( 28743549 )
2017
41
Insulinoma - The incremental value of somatostatin receptor positron emission tomography. ( 28217530 )
2017
42
Insulinoma Presenting with Neuropsychiatric Symptoms. ( 28782321 )
2017
43
A new marker, insulinoma-associated protein 1 (INSM1), for high-grade neuroendocrine carcinoma of the uterine cervix: Analysis of 37 cases. ( 27908529 )
2017
44
Hypoglycemia identified by a continuous glucose monitoring system in a second-trimester pregnant woman with insulinoma: a case report. ( 28427440 )
2017
45
Recurrence of Metastatic Pro-insulinoma Nearly 50A Years After Subtotal Pancreatectomy. ( 29110229 )
2017
46
A Clinicopathological Study of Malignant Insulinoma in a Contemporary Series. ( 27984486 )
2017
47
Non-surgical ablative therapies for inoperable benign insulinoma. ( 28755102 )
2017
48
A Case of Insulinoma Presenting with Reactive Hypoglycemia: Evaluating the Effect of Tumor Resection via Continuous Glucose Monitoring. ( 28943561 )
2017
49
Endoscopic Ultrasound-Guided Ethanol Ablation for Control of Local-Regional Metastatic Insulinoma. ( 28187109 )
2017
50
O-(2-(18)F-fluoroethyl)-l-tyrosine ((18)F-FET) uptake in insulinoma: first results from a xenograft mouse model and from human. ( 28793277 )
2017

Variations for Insulinoma

ClinVar genetic disease variations for Insulinoma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 MEN1 NM_000244.3(MEN1): c.371_372delTC (p.Val124Aspfs) deletion Pathogenic GRCh38 Chromosome 11, 64809738: 64809739
2 MEN1 NM_000244.3(MEN1): c.371_372delTC (p.Val124Aspfs) deletion Pathogenic GRCh37 Chromosome 11, 64577210: 64577211

Expression for Insulinoma

Search GEO for disease gene expression data for Insulinoma.

Pathways for Insulinoma

Pathways related to Insulinoma according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.72 ABCC8 GCG GCK GLP1R INS MEN1
2 12.29 GCG INS PDX1 WFS1
3
Show member pathways
12.13 GCG GLP1R IAPP SCT
4
Show member pathways
12.08 ABCC8 GCG GLP1R INS SLC2A2
5 11.87 GCG GLP1R IAPP SCT
6
Show member pathways
11.76 GCK INS PDX1 SLC2A2
7 11.65 GCG GCK SLC2A2
8
Show member pathways
11.54 ABCC8 GCK INS PDX1 SLC2A2
9
Show member pathways
11.1 GCK IAPP INS INSM1 PDX1 SLC2A2
10 11 ABCC8 GCK INS PDX1 SLC2A2
11 10.68 INS SLC2A2

GO Terms for Insulinoma

Cellular components related to Insulinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 secretory granule GO:0030141 9.33 CHGA PTPRN PTPRN2
2 transport vesicle membrane GO:0030658 9.13 CHGA PTPRN PTPRN2
3 endoplasmic reticulum lumen GO:0005788 9.02 GCG INS MEN1 PTPRN2 WFS1

Biological processes related to Insulinoma according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.83 GCG IAPP INS SCT SST
2 cellular protein metabolic process GO:0044267 9.76 IAPP INS MEN1 WFS1
3 glucose metabolic process GO:0006006 9.58 GCK INS PDX1
4 negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway GO:1902236 9.55 PDX1 WFS1
5 positive regulation of glycogen biosynthetic process GO:0045725 9.54 GCK INS
6 negative regulation of gluconeogenesis GO:0045721 9.52 GCK INS
7 positive regulation of cAMP metabolic process GO:0030816 9.51 CHGA IAPP
8 regulation of potassium ion transport GO:0043266 9.49 GCK KCNA5
9 negative regulation of blood vessel diameter GO:0097756 9.48 CHGA INS
10 glucose homeostasis GO:0042593 9.46 GCK INS PDX1 WFS1
11 insulin secretion involved in cellular response to glucose stimulus GO:0035773 9.37 PTPRN PTPRN2
12 negative regulation of type B pancreatic cell apoptotic process GO:2000675 9.32 PDX1 WFS1
13 detection of glucose GO:0051594 9.26 GCK PDX1
14 type B pancreatic cell differentiation GO:0003309 9.13 INSM1 MEN1 PDX1
15 regulation of insulin secretion GO:0050796 9.1 ABCC8 GCG GCK GLP1R KCNA5 SLC2A2

Molecular functions related to Insulinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.02 GCG IAPP INS SCT SST

Sources for Insulinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....